SLU-pp-322

SLU-PP-series compounds are small-molecule ERR-family agonists whose scaffold provides the structural basis for ligand-binding-domain engagement at the orphan nuclear receptors ERRα, ERRβ, and ERRγ. Detailed molecular-profile information for the specific lot in hand is established through the supplier's Certificate of Analysis. The compound's interaction profile in the published literature centers on ERR-family receptor activation with downstream investigations of mitochondrial-biogenesis markers, oxidative-phosphorylation-pathway intersection, and skeletal-muscle metabolic-pathway research in cell-culture and animal-model contexts. Pharmacokinetic descriptors documented in published studies include rapid absorption following oral paradigms in rodent investigations and moderate plasma residence under standard parenteral routes. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation of supplied lots is established by the lot-specific COA.

Experimental domains documented in the published literature for the SLU-PP series include ERRα / ERRβ / ERRγ ligand-binding-domain affinity studies, structure-activity investigations probing scaffold contributions to ERR-subtype selectivity, mitochondrial-biogenesis-marker assays in cell-culture systems, oxidative-phosphorylation-pathway research, skeletal-muscle metabolic-pathway investigations in rodent-model contexts, and screening assays for ERR-family-active small-molecule discovery. Investigators have also characterized SLU-PP-series compounds in comparative work alongside other ERR-active research scaffolds. Use in laboratory research extends to mechanism-elucidation paradigms where the small molecule serves as a defined ERR-family agonist reference. The reference material is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols and validated assay controls.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the supplier-COA-specified empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Counter-ion or solvate identity is confirmed when included in the lot's release specification. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA is the primary citation chain for this reference standard and records the lot identifier, manufacturing date, and analytical method versions used — providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the small-molecule reference standard should be held in its sealed, light-protected container at the temperature specified on the product label (typically 2–8°C or −20°C depending on the salt form and packaging). Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation. Reconstitution for in-vitro experimental use is typically performed in DMSO, water, or a researcher-selected solvent compatible with the downstream receptor-binding-assay or cell-culture-treatment buffer; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant solvent prior to extended storage. Avoid repeated freeze-thaw cycles. These handling parameters reflect general best-practice for small-molecule research compounds and do not constitute preparation guidance for human or veterinary application.